Multiple sclerosis is a complex disease, as several pathophysiological processes (including in¯ammation, demyelination, axonal damage and repair mechanisms) participate in the disease process. Furthermore, as new pathological evidence reveals, these processes are not uniformly represented across patient populations but can selectively predominate in individual patients, thus contributing to the heterogeneity in phenotypic expression of the disease, its prognosis and response to therapies. While the armamentarium of available therapies for multiple sclerosis broadens, little is known about factors that predict treatment response in individual patients to a speci®c drug. More importantly, we are beginning to understand that, analogous to cancer therapy, the successful therapeutic strategy in multiple sclerosis might ultimately involve the combination of different therapeutics targeting several dominant pathophysiological processes. The development of these process-speci®c therapies will be impossible without the use of biomarkers that re¯ect the targeted process, can select patient population in which the targeted process is prevailing and can aid during the more rapid screening of therapeutic agents in the early phase of their development. This review summarizes the general concepts of biomarkers and their potential use as surrogate endpoints and tailors these concepts to speci®c applications in multiple sclerosis research.
A type 0 biomarker is a marker of the natural history of a disease and correlates longitudinally with known clinical indices.
A type I biomarker captures the effects of a therapeutic intervention in accordance with its mechanism of action.
A surrogate endpoint is a biomarker that is intended to serve as a substitute for a clinically meaningful endpoint and is expected to predict the effect of a therapeutic intervention. The use of the term`surrogate marker' is discouraged.
A clinical endpoint is a clinically meaningful measure of how a patient feels, functions or survives. Clinical endpoints may be further classi®ed as intermediate endpoints, which are clinical endpoints that are not the ultimate outcome but are nonetheless of real clinical usefulness [e.g. exacerbation rate in relapsing±remitting MS (RR-MS)]; and ultimate clinical outcomes, which are clinical endpoints re¯ective of the accumulation of irreversible morbidity and survival (e.g. accumulation of irreversible disability in multiple sclerosis).
These de®nitions indicate a clear hierarchical distinction between biomarkers and surrogate endpoints. While numerous laboratory markers may be associated with a particular disease state, the term`surrogate' indicates the ability of a biomarker to provide information about the clinical prognosis or ef®cacy of a therapy. The word`surrogate' implies a strong correlation with a clinical endpoint, but in order to be clinically useful a surrogate must provide information about prognosis or therapeutic ef®cacy in a signi®cantly shorter time than would be needed by following the clinical endpoint.
Numerous criteria for the validation of the surrogacy of a biomarker have been proposed, both by statisticians and by clinicians/regulatory agencies (De Gruttola et al., 1997; Buyse et al., 2000; Hughes, 2002; Molenberghs et al., 2002) . Prentice de®ned two conditions that together are suf®cient to ensure the surrogacy of a biomarker (Prentice, 1989) . The ®rst requirement is a strong and signi®cant correlation between the biomarker and the clinical endpoint. The second condition requires that the biomarker fully capture the net effect of the treatment on the true clinical endpoint. In this context,`net effect' is de®ned as the cumulative effect accounting for all mechanisms of action, both bene®cial and harmful. As depicted schematically in Fig. 1A , it becomes obvious that the second of Prentice's conditions is extremely restrictive, and it represents the main reason for the failure of biomarkers to prove their surrogacy. Even if the biomarker correlates extremely well with clinical markers in natural history studies (depicted as a thick grey line showing the accumulation of clinical disability over time), in order to prove its surrogacy it would have to re¯ect collectively all positive (bene®cial) and negative (adverse) affects of the applied therapy. Clearly, this is virtually impossible, because some of the adverse effects of therapy may be completely unrelated to the pathophysiology of the disease and yet may negatively in¯uence the ultimate clinical endpoint [e.g. cardiotoxicity of linomide or mitoxantrone in multiple sclerosis Ghalie et al., 2002) ]. In multiple sclerosis the situation is further complicated by the fact that the disease pathophysiology is complex and the applied therapy may positively in¯uence only one of the contributing processes (e.g. effect of immunosuppressive therapies on in¯ammation) and have no effect, or potentially have even negative in¯uence on others. Understanding this limitation, the Food and Drug Administration (FDA) proposed a somewhat less restrictive criterion for considering evidence based on the use of biomarkers for drug approval purposes, where the second of Prentice's conditions is not reinforced if the biomarker is reasonably likely, on epidemiological, therapeutic, pathophysiological or other evidence, to predict clinical bene®t (1997) . However, approval under this section is subject to the requirement that the applicant studies the drug further to verify and describe its clinical bene®t in adequate and well-controlled post-marketing studies (1997) .
There are other reasons why biomarkers may fail to prove surrogacy to the clinical endpoint and these have been described previously (De Gruttola et al., 1997; Frank and Hargreaves, 2003) (Fig. 1B±F ). These reasons, leading to either false-negative or false-positive results, should always be kept in mind and tested for (if feasible) before the biomarker is selected for testing of surrogacy in large clinical trials. The two most obvious false-positive results are depicted in Fig. 1B and C. In both cases the changes in the biomarker re¯ect the effect of treatment, but these effects are either irrelevant to the pathophysiology of the disease (the Fig. 1 Relationship between biomarker and surrogate endpoint in therapeutic trials. (A) This scheme depicts the development of clinical disability during the natural history of the disease (the grey bar re¯ects the accumulation of clinical disability over time). The progression of disability may be altered during a therapeutic trial, depending on the ratio of all positive (bene®cial) and negative (side-effects or deleterious) effects of the applied therapy on the clinical parameters. Both positive (shades of purple) and negative (shades of blue) treatment effects may be stable during the whole therapy period, may be transient (i.e. decreasing during therapy) or may increase with the duration of treatment. The resulting relationship between all positive and negative effects of treatment will determine the extent of therapeutic bene®t, depicted as a divergence between the natural history of the disease and the new course of the disease (red bar) and its duration (slope of the red bar). The ideal surrogate endpoint correlates well with accumulation of disability in the natural history of the disease and in addition captures all (positive and negative) effects of treatment. Furthermore, the sensitivity of the biomarker measure must be signi®cantly greater than the sensitivity of clinical measurement (depicted as a thinner line for biomarkers and a thicker line for the clinical end-point), so that the biomarker measurement allows evaluation of the treatment effect in a signi®cantly shorter time than would be required by following the clinical endpoint. (B±F) These ®ve schemes depict the instances in which the evaluation of a biomarker (thick black line) in relation to clinical marker would lead to erroneous conclusions about the surrogacy of the biomarker.
biomarker does not correlate with clinical outcome in natural history; Fig. 1B ) or are clinically unimportant (the measurable change in the biomarker is not paralleled by the measurable change in the clinical endpoint; Fig. 1C ). Such false-positive surrogate markers are likely to emerge from the molecular/immunological studies supplementing therapeutic trials, which identify biomarkers re¯ective of the therapeutic intervention and possibly even of therapeutic ef®cacy.
However, their correlation with the clinical outcome that re¯ects the disease state still needs to be veri®ed. Examples of such biomarkers in multiple sclerosis is the use of MxA expression for determining the biological effect of interferonb (IFN-b) in vivo (Wandinger et al., 2001) , and a recently published study of using TNF-related apoptosis inducing ligand (TRAIL) as a biomarker of IFN-b therapeutic ef®cacy . Regardless how promising these results may appear, we cannot assume surrogacy of any of these biomarkers without ®rst demonstrating their strong correlation with the clinical outcome in an untreated multiple sclerosis population. Another potential false-positive result can emerge from a situation in which the changes in the biomarker re¯ect one effect of the treatment, but there are other, more signi®cant effects on outcome that are not captured by the biomarker (Fig. 1E) . Actually, this situation can cause both false-positive and false-negative results depending on whether the more profound effects on outcome (not captured by the biomarker) are predominantly negative or positive. In multiple sclerosis, the use of MRI measures in the linomide (Roquinimex) trial serves as an example of a false-positive result: while linomide therapy had a positive effect on brain contrast-enhancing lesions and on a composite MRI measure , this marker did not re¯ect the unanticipated cardiopulmonary toxicities that resulted in a poor clinical outcome in the treatment group and eventually led to premature termination of the trial . Similarly, we envisage that the putative biomarker could be signi®cantly in¯uenced by a transient negative effect of the therapy; the net therapeutic effect on the biomarker may thus be negative, despite the fact that the long-term clinical outcome (after cessation of the transient side-effect that was not clinically relevant) may be favourable (false-negative result). Another two causes of false-negative outcomes in the use of biomarkers as surrogate endpoints ( Fig. 1D and F) are very pertinent to multiple sclerosis, because it is a complex disease with multiple contributing pathophysiological mechanisms. A biomarker can lead to false-negative results in surrogacy testing if it re¯ects clinically relevant changes in pathophysiology but would not capture the mechanistic effects of the treatment applied (Fig. 1D ). For example, MRI measures of brain in¯ammation and accumulation of white matter lesion load (WMLL) cannot serve as useful biomarkers in measuring the therapeutic effect of a drug that has positive effects on remyelination and repair in multiple sclerosis. Finally, the biomarker might not correlate well with classical clinical markers if the biomarker is more sensitive than the clinical marker, or if the clinical marker is irrelevant to a subset of the patient population, to a novel mechanism of action of the drug or to its new indication (Fig. 1F) . Again, we need to ask how sensitive are our currently used clinical markers in depicting changes in the extent of remyelination and repair/scar formation after clinical attacks, especially if used short term. It is more than likely that a molecular/immunological biomarker re¯ecting the mechanism of action may be much more sensitive in this regard.
Although we conclude that, due to the complexity of multiple sclerosis pathophysiology, it is highly unlikely that we will ever ®nd a single biomarker in multiple sclerosis that completely substitutes for a meaningful clinical outcome, we believe that it is exactly for this reason (the complexity of this disease) that the development of biomarkers is essential for future drug development in multiple sclerosis and a better understanding of disease pathogenesis.
Use of the biomarkers for drug development in multiple sclerosis
The current costs of drug development are extraordinary, especially in the ®nal stages of clinical testing. Drug companies as well as regulatory agencies realize that faster screening of prospective therapies and earlier elimination of unpromising agents can substantially speed up drug development while limiting the associated cost. Moreover, the mechanism of action of many of the approved therapies is not fully established at the time when they go into clinical testing, or even at the time of their approval and widespread clinical use. This precludes the rational selection and design of combination therapies, and it renders the choice of the most ef®cacious therapy for a particular patient a guessing game for the treating physician. Wider employment of candidate surrogate markers during Phase I/II of clinical testing would lead to a better understanding of the mechanism of action of the tested drug, may help to stratify patients in terms of the potential effectiveness of an applied therapy, and ultimately will teach us important lessons about disease pathogenesis and patient heterogeneity.
In diseases with a complex pathogenesis, such as multiple sclerosis, an individual biomarker is likely to re¯ect only one of many ongoing pathogenic processes. As we pointed out above, this process-speci®city of a biomarker is a reason why it cannot serve as a surrogate for a clinical outcome in a complex disease. However, this relationship is mutual; it also implies that the clinical outcome, which is re¯ective of all contributory pathophysiological processes, is too insensitive to capture the full effect of any process-speci®c therapeutic application. The vast majority, if not all, currently approved therapies for multiple sclerosis target only the in¯ammatory component of multiple sclerosis pathophysiology (Bielekova and Martin, 1999) ; but it is becoming exceedingly clear that, if we want to successfully treat multiple sclerosis at later stages we will need to add treatments that affect other mechanisms, especially remyelination and repair. Furthermore, elegant pathological studies imply that, for some multiple sclerosis patients, the in¯ammatory component of the disease is less prominent and other factors, such as excitotoxicity or neurodegeneration might be the primary events for the accumulation of disability (Lucchinetti et al., 2000; Pitt et al., 2000) . Subsequently, there is a strong need for developing new therapies in multiple sclerosis that are more process-speci®c and can be used in speci®c patient subpopulations and possibly as sequential or simultaneous combination therapies. This important new direction in multiple sclerosis research will be unfeasible without the development of process-speci®c biomarkers. We performed a systematic analysis of all studies published within the last 20 years that examined biomarkers in multiple sclerosis, and concluded that none of the proposed biomarkers can serve as surrogate for clinical outcomes. This extensive work is clearly beyond the scope of the present review. However, perhaps even more importantly, more than 95% of the proposed biomarkers merely re¯ect different components of the in¯ammatory phase of the disease and there is a remarkable lack of suitable biomarker candidates re¯ective of other pathophysiological mechanisms. The reason for this lack of process-speci®c biomarkers is perhaps not too surprising: it is impossible to tease out speci®c pathogenetic processes in an unseparated patient population unless one studies very large cohorts of patients, which is not feasible in a disease as rare as multiple sclerosis at any single centre. Therefore, there are two possible ways to proceed. On the one hand, new candidate biomarkers in multiple sclerosis could emerge from the application of novel unbiased discovery tools (such as gene expression pro®ling, proteomics, metabolomics and biochemical pro®ling) in large patient cohorts from multicentre trials; on the other hand, hypothesisbased candidate biomarkers could be tested for their processspeci®city in carefully strati®ed patient populations (Lassmann et al., 2003) . In both instances this effort will require close cooperation among scientists from all areas of multiple sclerosis research (i.e. clinicians with pathologists, MRI specialists and molecular biologists) to ensure that the patient strati®cations from one area of research, such as pathology (Lucchinetti et al., 2000) , can be correlated with and enhanced by all other contributing specialities, such as MRI±pathological correlations (Barkhof and van Walderveen, 1999) . In this regard, we have recently proposed a MRI-based classi®cation of multiple sclerosis patients that is stable over time, has been validated in an independent cohort, and subdivides multiple sclerosis patients into four clinically meaningful subgroups (Bielekova et al., submitted) . We believe that this classi®cation may be the ®rst step in this multifaceted approach to the examination of disease heterogeneity in multiple sclerosis and will subsequently facilitate the development and testing of process-speci®c therapies.
The wide spectrum of potential roles that biomarkers will likely play in the future development of therapeutic applications in multiple sclerosis is summarized in Table 1 .
Proposed classi®cation of process-speci®c biomarkers in multiple sclerosis
The classi®cation of process-speci®c biomarkers in multiple sclerosis has to be based on careful evaluation of all contributing pathophysiological processes. On the basis of analysis of the published studies examining pathophysiological mechanisms in multiple sclerosis (Trapp et al., 1998; Genain et al., 1999; Pitt et al., 2000; John et al., 2002; Lassmann, 2002 Lassmann, , 1997 Lucchinetti et al., 2000) we were able to classify all biomarkers proposed so far in multiple sclerosis into one of these seven categories: Faster and more compelling con®rmation of ef®cacy (Phase III trials)
Better understanding of the mechanism of action of the tested drug by con®rmation of the presumed mechanisms that were established during preclinical studies Identi®cation of patients who will respond to the speci®c intervention in clinical practice
Providing a rationale for combination therapies and allowing the testing of therapeutic compatibilities between the two agents (preclinical and Phase I/II) (f) Biomarkers re¯ective of antigen processing and presentation (g) Other activation markers (h) Cell cycle and apoptosis-related biomarkers (i) Markers re¯ective of immune-mediated neuroprotection (j) Changes in cellular subpopulations (k) Functional assays for immunological reactivity (ii) Biomarkers of blood±brain barrier (BBB) disruption (iii) Biomarkers of demyelination (iv) Biomarkers of oxidative stress and excitotoxicity (v) Biomarkers of axonal/neuronal damage (vi) Biomarkers of gliosis (vii) Biomarkers of remyelination and repair
We will use this classi®cation when referring to methodological considerations in the measurement of immunological biomarkers and to the decision-making process for the selection of biomarkers for further development in multiple sclerosis.
Methodological considerations in the measurement of immunological biomarkers
The requirements for a biomarker, i.e. validity, speci®city and ease of measurement, will be quite different depending on its intended use [e.g. preclinical versus early clinical (Phase I/II) and late clinical (Phase III) stages of drug development]. Here, we brie¯y review the methodological considerations for the usefulness and applicability of a speci®c biomarker in multiple sclerosis.
(i) Markers indicative of different pathophysiological processes in multiple sclerosis
(a) Markers of immunological activation are likely tō uctuate with the relapsing±remitting course of the disease (similar to contrast-enhancing MRI activity), and therefore frequent serial measurements and the use of period averages (baseline versus treatment) may be necessary for the documentation of co-¯uctuation with disease activity and a treatment effect on this type of biomarker. Moreover, markers of immunological activation are signi®cantly in¯uenced by ongoing infectious processes and by circadian and menstrual cycles, and many are also affected by age and sex. Therefore, every effort should be made to standardize specimen collection in terms of collection time and time to processing, and to screen out samples that may have been in¯uenced by, for example, an infectious process. Due to multiple intertwined regulatory loops that are effective in vivo, the question of the clinical relevance of a change in a biomarker always emerges. This notion applies particularly to biomarkers that measure the effect of in vivo therapy, which will have much broader effects than those anticipated from in vitro testing. From a practical point of view, only biomarkers that can be obtained by non-invasive or minimally invasive procedures and evaluated by relatively simple and reliable assays may be considered as useful biomarkers from this group.
(b) Markers of demyelination, axonal damage, oxidative stress, gliosis and remyelination would be extremely valuable, since, based on experience with MRI markers of axonal damage (Barkhof and van Walderveen, 1999) , they may correlate better with the development of long-term disability, may have higher prognostic value and may signi®cantly enhance our understanding of the mechanism of action of tested therapies. These markers can be conceptually divided into positive and negative biomarkers. Positive biomarkers are biomarkers that are not produced (or occur only at very low levels) under physiological conditions, and are induced by the speci®c pathophysiological process in question. An example of such a marker would be glial ®brillary acidic protein (GFAP) in the CSF. These markers will be less desirable as surrogate endpoints because they are likely tō uctuate with disease activity and may not reliably represent the accumulated damage. Negative biomarkers, on the other hand, are produced under physiological conditions by intact tissues that are targeted by the disease process (e.g. insulin or pro-insulin in diabetes mellitus). Therefore, their decline will correspond to the accumulated damage in the target structures (oligodendrocytes, myelin and neurons in multiple sclerosis). These biomarkers are ideal, as they should correlate with the overall disability and can be assayed at two time-points: before and after therapy. Even biomarkers that must be obtained by invasive procedures only (like lumbar puncture in multiple sclerosis) should be considered as useful surrogate endpoints from this category, especially for use in Phase I/II clinical trials.
(ii) Type of specimen collected (a) Urine Advantages. The main advantage lies in its non-invasive collection and ability to be stored at the patient's home (±20°C). Collection of several hours' urine production (the ®rst morning urine collects a substance excreted during the night) can to some extent eliminate diurnal variation. The use of the biomarker/creatinine ratio may eliminate the need for 24 h urine collection (the biomarker/albumin ratio can be used to study the excretion of proteins and peptides that undergo signi®cant tubular reabsorption). Due to lower creatinine excretion in females, a correction factor (1.2) was proposed by some investigators (Giovannoni and Thompson, 1998) .
Disadvantages. chronic urinary tract infections and asymptomatic bacterial colonization of the bladder, which are both common in more-disabled multiple sclerosis patients, can negatively affect the results. In addition, patients with bladder instability may regulate their¯uid intake with resulting arti®cial hypohydration.
Currently measurable markers. Neopterin, nitrate and nitrite, prostaglandin metabolites, b 2 -microglobulin, immunoglobulin (Ig) light chains, interleukin (IL)-1, IL-2, sIL-2R Advantages. Blood is relatively simple to collect. The amount collected depends on the assay used and ranges from a few millilitres of whole blood/serum for PCR, ELISA and immuno¯uorescent studies to up to 120 ml, or even a leucocytapheresis, for extensive functional immunological studies.
Disadvantages. The main disadvantage is the diurnal variation of many soluble markers (e.g. IL-6 levels may vary as much as 350% during 24 h) and invasiveness of the collection. Levels of measured biomarkers are often affected by biological degradation in the liver or by excretion in the kidney. Separation techniques and storage (freezing) may affect the level of the studied marker, and therefore these have to be strictly standardized for assay reproducibility. Moreover, the time from collection to processing is absolutely critical, as delay in processing can signi®cantly alter the level of measured biomarkers, both by degradation of some of them (e.g. by activating serum proteases) and by arti®cial induction of the expression of others (unpublished personal observations).
Currently measurable markers. Unseparated blood can be used for¯ow cytometry analysis of cellular subpopulations and their functional phenotypization, and for PCR studies. After coagulation, serum can be used for the measurement of soluble markers such as antibodies and cytokines. After separation procedures of uncoagulated samples, different cellular populations can be used for functional studies.
(c) Cerebrospinal¯uid
Advantages. CSF may better re¯ect the relevant in¯ammatory process due to its proximity to in¯ammatory lesions in the CNS, although this notion remains controversial. Due to thē ow pattern of CSF, it is unlikely that the CSF in the lumbar cistern accurately re¯ects the production of the in¯ammatory markers in the supratentorial region, where most of the multiple sclerosis-related in¯ammation occurs. In addition, the intraparenchymal extracellular space may not necessarily communicate with the free CSF space (Giovannoni et al., 1998a) . However, CSF collection does prevent biological degradation of excreted markers by the liver or by renal excretion.
Disadvantages. CSF collection is an invasive, although relatively benign, procedure, and therefore can be used only in the experimental setting for a selected patient population and sampled only for a limited number of time-points. CSF production is not homogeneous; maximum CSF production occurs around 2 a.m. (42 T 2 ml/h) and minimum production around 6 p.m. (12 T 7 ml/h) (Giovannoni et al., 1998a) , and therefore the time of collection should be standardized. It remains unclear whether CSF markers possess de®nite advantages over markers collected from blood and/or urine.
Currently measurable markers. Cell populations in the CSF sample can be used for¯ow cytometry analysis, PCR studies and cell functional studies. Separated CSF can be used for measurements of soluble markers.
(d) Tears
An interesting pivotal study suggested the detection of oligoclonal bands in the tears of multiple sclerosis patients (Liedtke et al., 1992) and a follow-up study concluded that the speci®city and sensitivity of such detection is similar to that of CSF (Devos et al., 2001) . Due to the uninvasiveness of such approach, it should be investigated further whether tears may serve as a valuable biological material for other biomarker measurements.
Types of assay used for the measurement of surrogate marker (a) Enzyme-linked immunosorbent assay (ELISA)
ELISA is the most widely used assay for detecting soluble proteins in plasma. It has almost completely replaced the radioimmunoassay due to its lower cost and better safety pro®le. There are numerous commercially available kits for the detection of various proteins of interest and, following standardization protocols, the assays are easily reproducible in different laboratories. The other major advantage is the ability to use properly frozen and stored samples. The disadvantages are relatively low sensitivity and high cost. ELISA assays are useful for measurements of biomarkers in both Phase I/II and Phase III of clinical trials.
(b) Fluorescence immunoassays
Fluorescence-based immunoassays have, overall, a much broader potential than ELISA. They can detect proteins, peptides, haptens and antibodies with much higher sensitivity. Time-resolved¯uorescence immunoassays are among the most sensitive assays available today with sensitivities in the range of 10± 17 M. Fluorescence polarization immunoassays can reliably detect small peptides or haptens and ®bre-optic uoroimmunosensors enable multiple or continuous measurements of a biomarker in vivo. These assays are currently used widely in high-throughput screening in drug discovery, and it is very likely that they will replace the ELISA in clinical settings due to their signi®cantly higher sensitivity and very good reproducibility. Frozen samples can be used for analysis and, like ELISA, these assays should be useful in both early and later phases of clinical testing.
(c) Flow cytometry-based analyses
Flow cytometry is a relatively simple and reproducible means of studying cell subpopulations in whole or separated blood samples and to study the cell surface expression of different markers of interest. Newer approaches, such as vital uorescein dyes [e.g. 5-and 6-carboxy¯uorescein diacetate, succinimidyl ester (CFSE)] and intracellular cytokine staining, enable us to obtain also functional data about speci®c cell populations. However, in our experience the handling of the sample (time from sample collection to processing, separation procedures, freezing, acquiring fresh or paraformaldehyde-®xed samples) can signi®cantly in¯uence the results, especially if one attempts to compare the mean¯uorescence intensities (MFI) of measured markers. Mathematical modi®cations based on comparison of the MFIs of simultaneously acquired negative and positive controls can minimize at least some of these problems (Kraus et al., 1998) . Furthermore, these assays require specialized and expensive equipment. We believe that these assays are currently technically too tedious for widespread use in Phase III trials, but may be extremely useful for preclinical and Phase I/II trials.
(d) Polymerase chain reaction (PCR)
PCR-based techniques can reliably detect a single copy of genetic information. However, in order to be useful for the detection of surrogate markers, techniques need to be quanti®able. Quantitative PCR methods include non-competitive PCR, competitive PCR and real-time PCR (e.g. Taqman â ). Of these, we believe that only real-time PCR has the potential for widespread use in clinical trials, due to its relative methodological simplicity, reproducibility and speci®city. It is, however, very expensive. The greatest advantage of reverse transcription±PCR (RT-PCR) is the reliable and accurate analysis of minute amounts of mRNA and its ability to use properly frozen and stored samples. However, as with ow cytometry techniques, sample handling and delay in processing can have a signi®cant in¯uence on the results. Moreover, PCR-based methods exclude the detection of the post-translational modi®cations and regulatory mechanisms that may lead to decreased surface expression and/or function of the studied marker, and therefore the detected change may not be always translatable into functional relevance in vivo. As a result it is recommended that the functional relevance of the observed changes in PCR-based biomarker measurements should be assessed by different means (e.g.¯ow cytometry or functional assays). PCR techniques can be widely used across all stages of drug development.
(e) Cellular assays Primary proliferation, IL-7-modi®ed primary proliferation, split-well/limiting dilution analysis, ELISPOT. Most of these assays require relatively large quantities of blood and/or lymphocytapheresis, are time-consuming and are methodologically very challenging. The handling of the sample (delay in processing, separation techniques, freezing) may have signi®cant effects on the results. Many of these techniques require stimulation with speci®c antigen, and the selection of the stimulating antigen/s, its concentration and the stimulation conditions all affect the data. Depending on the antigen used, the responses may or may not have pathophysiological relevance in a given patient. Although some of these methods have been used as biomarkers in previous therapeutic trials (Bielekova et al., 2000) and although we believe that they have a ®rm place in the development of all antigenspeci®c immune interventions, they are limited to Phase I/II trials.
(f) New unbiased biomarker discovery techniques
As mentioned in the previous section, we believe that unbiased discovery tools, such as gene expression pro®ling, proteomics, metabolomics and biochemical pro®ling, which allow simultaneous analysis of the expression of thousands of genes, proteins or metabolites, will play a signi®cant role in the development of novel candidate biomarkers in every disease process, including multiple sclerosis. Thorough description of these techniques is beyond the scope of this review. However, the discovery-type studies published so far in the ®eld of multiple sclerosis (Wandinger et al., 2001; Whitney et al., 2001; Lock et al., 2002; Maas et al., 2002; Bomprezzi et al., 2003; Mycko et al., 2003) have revealed several problems that will need to be resolved before these techniques can yield more clinically applicable results. The ®rst and most important drawback of currently published studies is the enormous number of candidate genes that have been selected by each of these studies; unfortunately, these are largely non-overlapping. Additionally, very few of the studies have attempted to distinguish between the disease state and the disease phenotype (Maas et al., 2002) . We believe that progress in this ®eld is inevitable, but it will require the application of discovery tools in signi®cantly larger cohorts of patients and appropriate controls in order to increase the speci®city of selected candidate biomarkers and in order to start selecting biomarkers re¯ective of disease heterogeneity or of the treatment response (Sturzebecher et al., 2003) .
Decision-making in the selection of biomarkers for further development in multiple sclerosis
We have mentioned previously that we have undertaken a critical analysis of published studies in the ®eld of multiple sclerosis in the past 20 years (between 1982 and 2002; based on a Medline search) that propose multiple sclerosis-related laboratory biomarkers. We deliberately omitted MRI and other imaging biomarkers from this review because of previously established consensus on their use in multiple Proliferation assays (Ag-speci®c and polyclonal), cytokine-secretion assays, cytotoxic assays
Biomarkers of BBB disruption
It is unlikely that these biomarkers would become more useful than MRI-based markers of BBB dysfunction sclerosis (for review see McFarland, 2002) . In this section, we will summarize the criteria we used for the rating of published studies, the criteria that de®ne the characteristics of biomarkers that underline their clinical utility, and the criteria required for biomarker validation; and in one simpli®ed table (Table 2) we summarize the biomarkers that we considered in our review and choose those that, based on these extensive criteria, would in our opinion merit further development in multiple sclerosis.
Grading of the reviewed studies on the basis of recommendations of an evidence-based medicine working group
We graded each study that we reviewed according to the recommendations of the evidence-based medicine working group (Hayward et al., 1995; Jaeschke et al., 1994a, b Studies that ful®lled all ®ve criteria were considered grade A and those that ful®lled at least three criteria were considered grade B. All grade A and B studies were reviewed. All other studies were considered separately and were included only as preliminary study if they supported the biological rationale of the studied biomarker as a processspeci®c biomarker or as a potential surrogate endpoint.
Characteristics of a biomarker that underlie its potential clinical utility
The initial evaluation of a biomarker for its potential clinical utility can be based on determining how many of the characteristics of an ideal biomarker are met relative to the context of its use (Lesko and Atkinson, 2001) . We considered the following criteria for the evaluation of biomarkers in multiple sclerosis:
The biomarker should have a rational association with a particular pathogenic aspect in multiple sclerosis. For example, GFAP, which is a structural protein of the glial intermediate ®lament and in its soluble form is secreted into the CSF, is considered a biomarker of astrogliosis in neurodegenerative disorders. It is also a main protein constituent of chronic multiple sclerosis plaques. Therefore, it is a biologically reasonable candidate biomarker of astrogliosis in multiple sclerosis.
(ii) Clinical relevance
If a biomarker is to serve as surrogate endpoint (or even as a partial surrogate endpoint) it has to have, in addition to the biological rationale, the potential for clinical relevance; i.e. the biomarker has to be positioned in the causal chain of pathological events leading to a meaningful clinical endpoint. For example, it is not known whether gliosis (proliferation and migration of glial cells in damaged areas of the CNS) observed in multiple sclerosis has overall bene®cial (e.g. neuroprotective) or negative (e.g. preventing remyelination) effects on disease progression. Therefore, while GFAP may have a solid biological rationale, its clinical relevance in multiple sclerosis is currently unpredictable.
(iii) Practicality
The practical aspects of measurement of the biomarker (i.e. invasiveness of collection, need for serial analyses, the reproducibility, ease and cost of the assay) will to a large degree determine the context of its use (i.e. only exploratory/restricted use versus widespread clinical application).
(iv) Correlation with disease activity
Many of the published studies, especially those that investigated biomarkers of immune activation, related the studied biomarker to clinical or paraclinical measures of disease activity in multiple sclerosis. There are currently two types of accepted measures of disease activity in multiple sclerosis. The ®rst is clinical: the number of multiple sclerosis relapses per patient/year or the extent of progression in one of the disability scales over a period of time (progression index). The second is paraclinical: the number of contrast-enhancing lesions on MRI of the brain and accumulation of disease burden measured as WMLL, accumulation of T1 hypointensities (black hole volume, BHV) and increases in brain atrophy measures. However, these MRI measures of disease activity do not necessarily correlate with accumulated disability (the ultimate clinical measure in multiple sclerosis) (Li et al., 2001; Paolillo et al., 1999) , most likely because of the confounding effects of the locations and sizes of lesions, the severity of associated axonal damage, and the ability to remyelinate, which may be substantially different among individual patients. Several studies of correlation between immunological markers and measurements of MRI activity suggested that improving the quanti®cation of the MRI disease burden, both in¯ammatory and total (Rieckmann et al., 1997) , considering the temporal pro®le of contrastenhancing MRI lesions (Giovannoni et al., 1997) and taking into account anatomical relations of MRI lesions (Rieckmann et al., 1997) may signi®cantly enhance the correlation with immunological markers and possibly also with clinical endpoints (Giovannoni et al., 1998b) . Nevertheless, despite the current limitation of clinical and MRI measures of disease activity, they are widely used as outcomes in clinical trials, and the therapies that affect these measures may also demonstrate an effect on the long-term progression of disability (Jacobs et al., 1996; Durelli et al., 2002) .
(v) Correlation with disability/prognosis
Ultimately, the correlation of a biomarker with the accumulation of clinical disability in time is the most important characteristic for determining biomarker surrogacy.
(vi) Correlation with treatment effect
Therapies in¯uencing a biomarker should predictably in¯u-ence a clinical endpoint. Additionally, therapies with the same mechanism of action should in¯uence the biomarker congruently and comparatively with respect to their clinical effect. We considered reports of effects of biomarkers on all available therapies in multiple sclerosis (i.e. all formulations of IFN-b, glatiramer acetate, all formulations of glucocorticoids, and immunosuppressive agents, including mitoxantrone).
Evaluation criteria to de®ne the clinical usefulness of a biomarker
The evaluation of a biomarker is a complex process and the criteria and the strength of supporting evidence will differ according to the intended use of the biomarker. Obviously, the highest level of stringency is required when a biomarker is evaluated for its surrogacy to a clinical endpoint. However, biomarkers intended for other purposes (e.g. as a diagnostic tool, for staging of the disease or as an indicator of disease prognosis, facilitating understanding of the disease mechanisms, selection for process-speci®c application, or probing for mechanisms of the treatment effect in proof-of-principle studies) do not need to be evaluated as rigorously and may still play very important roles. The different evaluation criteria for biomarkers (2001; Lesko and Atkinson, 2001 ) are summarized below.
(i) Sensitivity/speci®city These are standard statistical evaluations comparing a new marker (i.e. biomarker) with a gold standard marker (i.e. a clinical endpoint). Sensitivity refers to the ability to measure the biomarker with the magnitude of change that would be suf®cient to re¯ect a clinically relevant endpoint (the incorrectly predicted values would be described as`false negative'; i.e. the biomarker would not be able to distinguish a small but still meaningful change in clinical endpoint). Speci®city refers to the accuracy with which the biomarker is able to distinguish correctly between the two clinically relevant endpoints (incorrectly predicted values would be described as`false positive'; i.e. the biomarker would distinguish changes that are not re¯ected in a clinically meaningful endpoint).
(ii) Reliability
The reliability of a biomarker can be assessed in several ways: as the consistency of a measurement in time (biological variation), the consistency of a measurement dependent on an assay method (intra-and inter-assay variability) and the consistency of measurement based on the probability of false-positive and false-negative results.
(iii) Evaluation of a biomarker in epidemiological studies or natural history cohorts These studies are essential for establishing the statistical relationship between the biomarker and the clinical endpoint under basal conditions. Such data may emerge from largescale cross-sectional studies or, ideally, from longitudinal natural history studies. However, in view of the available partially effective therapies, the prospective use of long-term natural history cohorts has become ethically unsupportable at the present time in multiple sclerosis.
(iv) Evaluation of a biomarker in proof-ofprinciple clinical trials
Biomarkers that re¯ect the anticipated mechanism of action of the tested drug should in our opinion always accompany Phase I/II proof-of-principle trials, because their use can signi®cantly enhance our understanding not only of drug action but also of the disease process. By using the precursor frequency of MBP(83±99)-speci®c T cells and alteredpeptide ligand (APL)-speci®c T cells in a proof-of-principle therapeutic trial of an APL based on the MBP(83±99) sequence, we obtained invaluable information about the potential for cross-reactivity between the two epitopes that was completely unforeseen from in vitro data, and also established that MBP(83±99)-speci®c T cells indeed have encephalitogenic potential in humans under certain circumstances (Bielekova et al., 2000) . Without these data, we could today only hypothesize on the reason for the occurrence of atypical multiple sclerosis exacerbations in some patients during APL therapy (Bielekova et al., 2000) , and we would not be able to formulate the criteria for improving risk to ef®cacy ratio in the design of possible future APL-based therapies (Bielekova and Martin, 2001 ).
Evaluation of a biomarker in large multicentre double-blinded therapeutic trials
According to Hughes, only randomized controlled clinical trials can distinguish a surrogate endpoint from a mere marker of drug activity (Hughes et al., 1995) . In addition, such studies can estimate the proportion of a treatment effect that is accounted for by the biomarker/surrogate endpoint, and the evaluation of placebo arm can provide invaluable information about the surrogacy of the biomarker in an untreated population.
Evaluation of a biomarker in meta-analyses and mathematical modelling of the biomarker± clinical endpoint relationship
The ultimate estimation of the proportion of a treatment effect that is re¯ected by the biomarker comes from meta-analyses of treatment effects on the same biomarker in a series of trials in which different classes of therapies are evaluated using the same clinical endpoint (2001; Hughes et al., 1995) . Therefore, in order to validate the surrogacy of a biomarker in multiple sclerosis, investigators must collaborate in order to design large trials that incorporate marker evaluation and at the same time adhere to standardized methods that would allow potential surrogate endpoints to be evaluated in a metaanalysis.
Summary and conclusion
In the moment there is no biomarker available that ful®ls the criteria of a surrogate endpoint in multiple sclerosis. Disappointing as this conclusion may be, it is also becoming clear that biomarkers will play a very important role in multiple sclerosis research and clinical practice in the future.
Due to their¯uctuating nature, biomarkers of immune activation are unlikely to show surrogacy even after extensive additional studies. However, some of them may prove extremely useful in de®ning disease heterogeneity in multiple sclerosis and thus in stratifying patients into distinct subgroups. As suggested by pathological data, dysfunctional or imbalanced immune processes (e.g. complement activation, autoantibodies, cell-mediated lysis) may predominate in some patient subgroups. Here, the establishment of biomarkers that re¯ect these processes in vivo would be essential in studying disease heterogeneity and assessing how different phenotypes correlate with or allow the prediction of the response to novel process-speci®c therapies. Additionally, there is a great need to identify and develop novel candidate biomarkers in multiple sclerosis that would re¯ect other contributing pathophysiological mechanisms, viz. oxidative stress and excitotoxicity, demyelination and remyelination, gliosis, neurodegeneration and repair. These candidate biomarkers will probably evolve from the unbiased discovery techniques of gene expression pro®ling, proteomics and pharmacogenomics. These approaches offer the opportunity to progress from the examination of single genes or proteins to the study of entire systems, such as cell metabolism, expression and the regulation of proin¯ammatory proteins, apoptosis. Obviously, while such studies have only begun, they are probably appropriate in addressing the complex immune or tissue alterations in multifaceted diseases such as multiple sclerosis.
Clearly, more uni®ed efforts are needed in the standardization of collection techniques and measurement methods, in order to allow comparison of the results from multiple studies. With the ethically imposed limitation on the study of untreated multiple sclerosis cohorts in the long term and the overall limit on patient resources, further biomarker research should be pursued in a coordinated, ideally international, effort similar to the one that has greatly advanced the use of MRI in multiple sclerosis. In our opinion, clinical trials should always be accompanied by biomarker studies oriented towards mechanisms of action. Investigators and sponsors should both understand that large multicentre clinical trials are becoming the only source of patient cohorts that are suf®ciently large and de®ned to enable the evaluation of biomarkers for their surrogacy in multiple sclerosis, and that extra resources need to be allocated to biomarker discovery, since their evaluation will be crucial for the advancement of clinical and basic multiple sclerosis research.
